ESB 1609
Alternative Names: ESB-1609Latest Information Update: 28 Feb 2023
Price :
$50 *
At a glance
- Originator AbbVie
- Developer E-Scape Bio
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Niemann-Pick disease type C; Parkinson's disease
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for phase-I development in Niemann-Pick-disease-type-C(In volunteers) in USA (PO)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in USA (PO)
- 24 Feb 2021 E-Scape Bio plans phase Ib/IIa biomarker trials for Niemann-Pick disease type C and Parkinson's disease (E-Scape Bio pipeline, Jul 2020)